Professor Oliver Ottmann



Prosiectau fel Prif Ymchwiliwr
null null 1 o 4 null null

Acute myeloid leukaemia or high risk myelodysplastic syndrome - Cyllidwr:CTI BioPharma Corp (01.08.2014 - 31.07.2017)
AML 18 pilot study - Cyllidwr:Genzyme Therapeutics Limited (08.03.2011 - 28.02.2018)
UK NCRN LI-1 trial - Cyllidwr:Sunesis Pharmaceuticals Inc (01.04.2012 - 31.12.2018)


Prosiectau fel Cyd-Ymchwiliwr

Biomarker discovery for acute myeloid leukaemia using a proteomic approach - Cyllidwr:Medical Research Council (01.10.2016 - 31.03.2017)
HLA-agnostic T-cell receptor for treatment of haematological malignancies - Cyllidwr:Kay Kendall Leukaemia Fund (01.01.2019 - 30.06.2021)

Diweddarwyd y tro diwethaf ar 2020-25-10 am 05:08